摘要
缺血性脑卒中(Ischemic Stroke, IS)是我国成年人致残、致死的首位疾病,其损伤机制复杂。目前,静脉溶栓、动脉取栓是缺血性脑卒中脑血管再通的重要方法,但由于治疗时间窗的限制,只有不到5%的患者能够接受脑血管再通治疗。我国自主研发的1类新药依达拉奉右莰醇(edaravone-dexborneol)是由依达拉奉和右莰醇以4:1的比例组成的神经保护剂,用于改善缺血性脑卒中所致的神经功能障碍。本文将概述依达拉奉右莰醇在缺血性脑卒中的作用机制,为其治疗缺血性脑卒中的治疗提供理论依据。
Ischemic stroke (IS) is the leading cause of adult disability and death in our country. At present, in-travenous thrombolysis and arterial thrombectomy are important methods for cerebral vascular recanalization in ischemic stroke. However, less than 5% of patients with ischemic stroke can be treated with recanalization because of the treatment time window (<4.5 hours). Edara-vone-dexborneol, a new drug developed in our country, is a neuroprotective agent composed of edaravone and dexborneol in a ratio of 4:1. This article will summarize the mechanism of edaravone right camphor in the treatment of ischemic stroke, and provide theoretical basis for its treatment of ischemic stroke.
出处
《临床医学进展》
2023年第6期9947-9951,共5页
Advances in Clinical Medicine
